Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis.
Daniel E WeinerThilo SchauflerKieran McCaffertyNuri B HasbalMichael J GermainDespina RuessmannIsabelle MorinFrédérique MenzaghiWarren WenSonja StänderPublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023)
In patients undergoing haemodialysis with moderate-to-severe CKD-aP, itch reduction with intravenous difelikefalin was associated with improved sleep quality. As disturbed sleep may contribute to mortality and morbidity in CKD-aP, difelikefalin may help to address a major clinical burden by improving sleep quality, secondary to itch relief.